A Clinical Trial of the P-Glycoprotein Antagonist, XR9576, in Combination With Vinorelbine in Patients With Cancer: Analysis of the Interaction Between XR9576 and Vinorelbine

Study start date: December 1, 1999

Age greater than or equal to 18 years. Histologic or cytologic confirmation of cancer, for which there is no known standard therapy capable of extending life expectancy. Performance status ECOG 0-2. Life expectancy of 3 months or greater. Platelet count greater than or equal to 90,000/mL. Absolute granulocyte count (AGC) greater than or equal to 1,000/mL. Serum creatinine less than or equal to 1.5 mg/dl (or if greater than 1.5, measured creatinine clearance greater than or equal to 50 mL/min). SGPT and SGOT less than or equal to 2.5 times normal limit, and bilirubin less than or equal to 1.5 times normal limit (in patients with clinical evidence of Gilbert's disease, less than or equal to 3 times normal limit). 2 weeks from prior radiation or chemotherapy and recovery from associated toxicities such that they meet eligibility criteria. Hormonal therapy may be taken up to the time of enrollment. No serious intercurrent medical illness. Bidimensionally measurable disease by radiographic means or physical examination; or relevant tumor markers (i.e. CA-125 and PSA greater than or equal to 2 times upper limit of normal). The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol. No pregnant or nursing women; or women of childbearing potential unless using effective contraception as determined by the patient's physician. No history of another malignancy; specifically, no patients with a non-skin malignancy or with melanoma within the past 5 years; no concomitant malignancy that has not been curatively treated. However, cancer survivors who have undergone potentially curative therapy for a prior malignancy at least 5 years before enrollment is considered, and are deemed at low risk for recurrence by their treating physicians. No patients with current or a history of CNS metastases. No patients who are a poor medical risk because of other non malignant systemic disease or active, uncontrolled infection. No HIV seropositive patients. No prior vinorelbine therapy.